EUVIMEDEUVIMED entdecken
BeobachtungsstudieMultizentrische StudieOpen Access · CC BY 4.0

Saving Beds and Budgets: Real-World Efficacy, Safety, and Pharmacoeconomics of Long-Acting Lipoglycopeptides (LALs) in a Day Hospital Setting

Andrea Marino iD, Emmanuele Venanzi Rullo iD, Giuseppe Pipitone iD, Alessandro Giorgio Geremia, Andrea De Vito iD, Antonio Albanese iD, Nicholas Geremia iD, Alessandro Franzò iD, Federica Cosentino, Paolo Italia, Maria Elena Ciuppa iD, Andrea Buzzi und 8 weitere

Pathogens · 14.07.2026 · 15 (7) · 740

DOI: 10.3390/pathogens15070740 ↗

Kurz gefasst

Beobachtungsstudie in der Zeitschrift Pathogens, online erschienen am 14.07.2026. Verfasst von Andrea Marino und 19 weiteren Autor:innen. Beteiligte Einrichtung: Infectious Diseases Unit, Department of Clinical and Experimental Medicine, ARNAS Garibaldi Hospital, University of Catania, 91122 Catania, Italy. Hauptthemen laut MEDLINE: Anti-Bacterial Agents, Gram-Positive Bacterial Infections, Lipoglycopeptides. Die Arbeit nennt 21 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Long-acting lipoglycopeptides (LALs), including dalbavancin and oritavancin, may facilitate outpatient-oriented management of Gram-positive infections by reducing the need for prolonged hospitalization and daily intravenous therapy. However, real-world evidence on their use in day hospital pathways, particularly for complex off-label infections, remains limited. This study evaluated the clinical effectiveness, safety, and economic impact of LAL-based day hospital management, comparing in-label acute bacterial skin and skin-structure infections (ABSSSI) with complex off-label indications.

Methods

This retrospective, multicenter observational study included 160 adult patients treated with dalbavancin and/or oritavancin in a day hospital setting across nine Italian centers between January 2020 and December 2025. Indications were classified as in-label ABSSSI or off-label infections, including osteomyelitis, prosthetic joint infection, spondylodiscitis, endocarditis, septic arthritis, and prosthetic cardiac infection. The primary endpoint was clinical success at final follow-up. Secondary endpoints included adverse drug events, readmissions, inflammatory marker response, and a budget impact cost-offset analysis based on avoided inpatient bed-days.

Results

Overall, 54.4% of patients received LALs for off-label indications, mainly osteomyelitis, prosthetic joint infection, and spondylodiscitis. Clinical outcome was available for 159 patients, with an overall success rate of 86.8% (138/159). Success rates were 90.4% for in-label ABSSSI and 83.7% for off-label indications, with no statistically significant difference between groups (p = 0.247). In exploratory analyses, monotherapy was associated with lower failure odds; this most likely reflects confounding by indication and should not be interpreted as a treatment effect. Inflammatory markers significantly decreased from baseline to end of therapy. Adverse drug events were uncommon (3.3%), mild, and did not lead to treatment discontinuation. In a scenario-based cost-offset model (no matched inpatient comparator), the strategy corresponded to 1107–2214 avoided inpatient bed-days; estimated net savings ranged from approximate cost-neutrality under conservative assumptions (€11,976) to €676,176 under maximum assumptions, and one-way sensitivity analysis showed a possible net loss at low inpatient daily-cost values—underscoring that these are modeled rather than observed savings.

Conclusions

In this uncontrolled, retrospective cohort, LAL-based day hospital management was feasible and associated with favorable observed clinical outcomes, an acceptable safety profile, and a potential for cost offset in selected patients with Gram-positive infections, including complex off-label indications. Because no matched inpatient or conventional OPAT comparator was included, these findings should be regarded as hypothesis-generating and cannot establish comparative efficacy, superiority, or actual cost savings.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Anti-Bacterial AgentsGram-Positive Bacterial InfectionsLipoglycopeptidesAdultAgedFemaleHumansMaleMiddle AgedBudgetsDay Care, MedicalEconomics, PharmaceuticalItalyRetrospective StudiesTeicoplaninTreatment OutcomeVancomycin

Stichwörter der Autor:innen

Gram-positive infectionsOPATdalbavancinday hospitallong-acting lipoglycopeptidesoritavancin

Substanzen

Anti-Bacterial AgentsdalbavancinLipoglycopeptidesoritavancinTeicoplaninVancomycin

Autor:innen und Institutionen

  • Infectious Diseases Unit, Department of Clinical and Experimental Medicine, ARNAS Garibaldi Hospital, University of Catania, 91122 Catania, Italy.
  • Unit of Infectious Diseases, Department of Clinical and Experimental Medicine, University of Messina, 98124 Messina, Italy.
  • Infectious Diseases Unit, ARNAS Civico-Di Cristina, 90127 Palermo, Italy.
  • Unit of Infectious Diseases, "G. Rodolico-S. Marco" University Hospital, University of Catania, 95121 Catania, Italy.
  • Unit of Infectious Diseases, Department of Medicine, Surgery and Pharmacy, University of Sassari, 07100 Sassari, Italy.
  • Infectious Diseases Unit, Ospedale Papardo, 98124 Messina, Italy.

ORCID-Profile: Andrea Marino, Emmanuele Venanzi Rullo, Giuseppe Pipitone, Andrea De Vito, Antonio Albanese, Nicholas Geremia, Alessandro Franzò, Maria Elena Ciuppa, Giordano Madeddu, Giuseppe Nunnari

Zitieren

APA

Marino, A., Venanzi Rullo, E., Pipitone, G., Geremia, A. G., De Vito, A., Albanese, A., Geremia, N., Franzò, A., Cosentino, F., Italia, P., Ciuppa, M. E., Buzzi, A., Santoro, L., Iaria, C., Madeddu, G., Iacobello, C., Manuele, R., Pulvirenti, F., Cacopardo, B., & Nunnari, G. (2026). Saving Beds and Budgets: Real-World Efficacy, Safety, and Pharmacoeconomics of Long-Acting Lipoglycopeptides (LALs) in a Day Hospital Setting. Pathogens, 15(7), 740. https://doi.org/10.3390/pathogens15070740

Vancouver

Marino A, Venanzi Rullo E, Pipitone G, Geremia AG, De Vito A, Albanese A, et al. Saving Beds and Budgets: Real-World Efficacy, Safety, and Pharmacoeconomics of Long-Acting Lipoglycopeptides (LALs) in a Day Hospital Setting. Pathogens. 2026;15(7):740. doi:10.3390/pathogens15070740

BibTeX
@article{Marino2026,
  author = {Marino, Andrea and Venanzi Rullo, Emmanuele and Pipitone, Giuseppe and Geremia, Alessandro Giorgio and De Vito, Andrea and Albanese, Antonio and Geremia, Nicholas and Franzò, Alessandro and Cosentino, Federica and Italia, Paolo and Ciuppa, Maria Elena and Buzzi, Andrea and Santoro, Laura and Iaria, Chiara and Madeddu, Giordano and Iacobello, Carmelo and Manuele, Rosa and Pulvirenti, Fabrizio and Cacopardo, Bruno and Nunnari, Giuseppe},
  title = {Saving Beds and Budgets: Real-World Efficacy, Safety, and Pharmacoeconomics of Long-Acting Lipoglycopeptides (LALs) in a Day Hospital Setting},
  journal = {Pathogens},
  year = {2026},
  volume = {15},
  number = {7},
  pages = {740},
  doi = {10.3390/pathogens15070740}
}
Kostenlos starten →